Systemic therapies for recurrent and/or metastatic salivary gland cancers

Expert Review of Anticancer Therapy

Volumn 8, Issue 3, 2008, Pages 393-402

  Vattemi, Emanuela ^a   Graiff, Claudio ^a   Sava, Teodoro ^b   Pedersini, Rebecca ^a   Caldara, Alessia ^c   Mandarà, Marta ^d  

^a Central Regional Hospital   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c SANTA CHIARA HOSPITAL   (Italy)

^d Section of Onco Hematology   (Italy)

Author keywords

Chemotherapy; Radiation therapy; Salivary tumors; Surgery; Targeted therapy

Indexed keywords

ANTHRACYCLINE; ANTIANDROGEN; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; LAPATINIB; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; SORAFENIB; TRASTUZUMAB;

ADENOCARCINOMA; ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ADVANCED CANCER; ANOREXIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER INVASION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GROWTH RATE; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHADENECTOMY; METASTASIS POTENTIAL; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; POSTOPERATIVE CARE; PRACTICE GUIDELINE; RECURRENT CANCER; REVIEW; SALIVARY GLAND CANCER; SALIVARY GLAND CARCINOMA; SALIVARY GLAND TUMOR; SKIN TOXICITY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BORONIC ACIDS; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; PIPERAZINES; PYRAZINES; PYRIMIDINES; QUINAZOLINES; SALIVARY GLAND NEOPLASMS;

EID: 45249100192     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.3.393     Document Type: Review

References (56)

1. Davies L, Welch HG. Epidemiology of head and neck cancer in the United States. Arch. Otolaryngol. Head Neck Surg. 135(3) 451-457 (2006).
2. Speight PM, Barrett AW. Salivary gland tumours. Oral Dis. 8(5), 229-240 (2002).
3. Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours. Barnes L, Eveson JW, Reichart PA, Sidransky D (Eds). IARC Press, Lyon, France (2005).
4. Greene FL, Page DL, Fleming ID et al. AICC Cancer Staging Handbook, 6th Edition. Springer, NY, USA 69-77 (2002).
5. Witt RL. Major salivary gland cancer. Surg. Oncol. Clin. N. Am. 13(1), 113-127 (2004).
6. Harrison LB, Armstrong JG, Spiro RH et al. Postoperative radiation therapy for major salivary gland malignancies. J. Surg. Oncol. 45(1), 52-55 (1990).
7. Terhaard CH, Lubsen H, Rasch CR et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int. J. Radiat. Oncol. Biol. Phys. 61(l), 103-111 (2005).
8. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J. Clin. Oncol. 24 (17), 2673-2678 (2006).
9. Licitra L, Marchini S, Spinazze S et al. Cisplatin in advanced salivary gland carcinoma. A Phase II study of 25 patients. Cancer 68(9), 1874-1877 (1991).
10. Airoldi M, Pedani F, Succo G et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91(3), 541-547 (2001).
11. Gilbert J, Li Y, Pinto HA et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 28(3), 197-204 (2006).
12. Piechocki M, Lonardo F, Ensley JF et al. Anticancer activity of docetaxel in murine salivary gland carcinoma. Clin. Cancer Res. 8(3), 870-877 (2002).
13. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med. 357(17), 1705-1715 (2007).
14. Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl. J. Med. 357(17), 1695-1704 (2007).
15. Raguse JD, Gath HJ, Bier J et al. Docetaxel (Taxotere) in recurrent high grade mucoepidermoid carcinoma of the major salivary glands. Oral Oncol. 40(1), 5-7 (2004).
16. Alberts DS, Manning MR, Coulthard SW et al. Adriamycin/ cis-platinum-cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Cancer 47(4), 645-648 (1981).
17. Creagan ET, Woods JE, Schutt AJ et al. Cyclophosphamide, adriamycin, and cis-diamminedichloro-platinum in the treatment of advanced non-squamous cell head and neck cancer. Cancer 52 (11), 2007-2010 (1983).
18. Dreyfuss AI, Clark JR; Fallon BG et al. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer 60 (12), 2869-2872 (1987).
19. Eisenberg MA. Supporting evidence for an active treatment program for advanced salivary gland carcinomas. Cancer Treat. Rep. 69, 319-321(1985).
20. Veenok AP, Tseng A, Meyers FJ et al. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J. Clin. Oncol. 5(6), 951-955 (1987).
21. Airoldi M, Fornari G, Pedani F et al. Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res. 20(5C), 3781-3783 (2000).
22. Laurie SA, Su YB, Pfister DG. Chemotherapy in the management of metastatic adenoid cystic carcinoma: a systematic review. J. Clin. Oncol. 23, S520 (2005) (Abstract 5581).
23. Edwards PC, Bhuiya T, Kelsch RD. C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 95(5), 586-593 (2003).
24. Mino M, Pilch BZ, Faquin WC. Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma. Mod. Pathol. 16(12), 1224-1231 (2003).
25. Penner CR, Folpe AL, Budnick SD. C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Mod. Pathol. 15(7), 687-691 (2002).
26. Hotte SJ, Winquist EW, Lamont E et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital Phase II consortium study. J. Clin. Oncol. 23(3), 585-590 (2005).
27. Ochel HJ, Gademann G, Rocken C et al. Effects of imatinib mesylate on adenoid cystic carcinomas. Anticancer Res. 25(5), 3659-3664 (2005).
28. Lin CH, Yen RF, Jeng YM et al. Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. Head Neck 27(12), 1022-1027 (2005).
29. Alcedo JC, Fabrega JM, Arosemena JR et al. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: Report of two successfully treated cases. Head Neck 26 (9), 829-831 (2004).
30. Guigay JM, Bidault F, Temam S et al. Antitumour activity of imatinib in progressive, highly expressing KIT adenoid cystic carcinoma of the salivary glands: a Phase II study. Proc. Am. Soc. Clin. Oncol. 25, S508 (2007) (Abstract 6086).
31. Faivre S, Raymond E, Casiraghi O et al. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J. Clin. Oncol. 23(25), 6271-6273 (2005).
32. Bruce IA, Slevin NJ, Homer JJ et al. Synergistic effects of imatinib (STI571) in combination with chemotherapeutic drugs in head and neck cancer. Anticancer Drugs. 16(7), 719-726 (2005).
33. Slevin NJ, Mais KL, Bruce I et al. Imatinib with cisplatin in recurrent and/or metastatic salivary adenoidcystic carcinoma - response assessed by FDG-PET scanning. J. Clin. Oncol. ASCO Ann. Meet. Proc. 22(14), 5604 (2004).
34. Glisson B, Colevas AD, Haddad R et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin. Cancer Res. 10(3), 944-946 (2004).
35. Dori S, Vered M, David R et al. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. J Oral Pathol. Med. 31(8), 463-467 (2002).
36. Nguyen LH, Black MJ, Hier M et al. HER2/neu and Ki-67 as prognostic indicators in mucoepidermoid carcinoma of salivary glands. J Otolarlyngol. 32(5), 328-331 (2003).
37. Skálová, Stárek I, Vanecek T et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 42(4), 348-356 (2003).
38. Dagrada GP, Negri T, Tamborini E et al. Expression of HER-2/ neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in situ hybridization and immunohistochemistry. Histopathology 44(3), 301-302 (2004).
39. Haddad R, Colevas AD, Krane JF et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas: a Phase II study. Oral Oncol. 39 (7), 724-727 (2003).
40. Prat A, Parera M, Reyes V et al. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck (2007) (Epub ahead of print).
41. Haddad R, Posner MR. Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent Phase II studies with trastuzumab and gemcitabine. Clin. Adv. Hematol. Oncol. 1(4), 226-228 (2003).
42. Locati LD, Rinaldi G, Bossi P et al. Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. Oral Oncol. 41(1), 97-98 (2005).
43. Vered M, Braunstein E, Buchner A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 24 (7), 632-636 (2002).
44. Chen CH, Liu BY, Wan JT et al. Expression of epidermal growth factor in salivary gland adenoid cystic carcinoma. Proc. Natl Sci. Counc. Repub. China B 25 (2), 90-96 (2001).
45. Gibbons MD, Manne U, Carroll WR et al. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope 111(8), 1373-1378 (2001).
46. Katopodi E, Patsouris E, Papanikolaou V et al. Immunohistochemical detection of epidermal growth factor and its receptor in salivary gland carcinomas. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 95(3), 266-268 (2003).
47. Fan CY, Melhem MF, Hosal AS et al. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor α in salivary duct carcinoma. Arch. Otolaryngol. Head Neck Surg. 127 (9), 1075-1079 (2001).
48. Glisson BS, Blumenschein G, Francisco M et al. Phase II trial of gefitinib in patients with incurable salivary gland cancer. J. Clin. Oncol. ASCO Ann. Meet. Proc. 23(Suppl.16) 5532 (2005).
49. Licitra LF, Locati LD, Potepan P et al. Cetuximab (C225) in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): a monoinstitutional Phase II study. J. Clin. Oncol. ASCO Ann. Meet. Proc. 24(Suppl. 18) 5547 (2006).
50. Argiris A, Goldwasser MA, Burtness B et al. A Phase II of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. ASCO Ann. Meet. Proc. 24(Suppl. 18) 5573 (2006).
51. Agulnik M, Cohen EW, Cohen RB et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J. Clin. Oncol. 25(25), 3978-3984 (2007).
52. Dori S, Trougouboff P, David R et al. Immunohistochemical evaluation of estrogen and progesterone receptors in adenoid cystic carcinoma of salivary gland origin. Oral Oncol. 36(5), 450-453 (2000).
53. Shadaba A, Gaze MN, Grant HR. The response of adenoid cystic carcinoma to tamoxifen. J. Laryngol. Otol. 111(12), 1186-1189(1997).
54. Nasser SM, Faquin WC, Dayal Y. Expression of androgen, estrogen and progesterone receptors in salivary gland tumors: frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am. J. Clin. Pathol. 119(6), 801-806 (2003).
55. Locati LD, Quattrone P, Bossi P et al. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann. Oncol. 14(8), 1327-1328 (2003)
56. van der Hulst RW, van Krieken JH, van der Kwast TH et al. Partial remission of parotid gland carcinoma after goserelin. Lancet 344(8925), 817 (1994).